Met Life Investment Management, LLC Allogene Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 53,147 shares of ALLO stock, worth $116,923. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,147
Previous 59,140
10.13%
Holding current value
$116,923
Previous $137,000
8.03%
% of portfolio
0.0%
Previous 0.0%
Shares
40 transactions
Others Institutions Holding ALLO
# of Institutions
163Shares Held
134MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$41.2 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$36.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$18.3 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$15.4 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$15.2 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $316M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...